Edwards Lifesciences Stock News

Vontobel Holding Ltd. raised its holdings in Edwards Lifesciences Co. (NYSE:EW) by 7.7% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 261,812 shares of the medical research companys stock after purchasing an additional 18,812 shares during the quarter. Vontobel Holding Ltd.s holdings []

Texas Permanent School Fund lowered its stake in Edwards Lifesciences Co. (NYSE:EW) by 6.8% during the third quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 96,295 shares of the medical research companys stock after selling 6,977 shares during the quarter. Texas Permanent School Funds holdings in []

Kovitz Investment Group Partners LLC reduced its position in Edwards Lifesciences Co. (NYSE:EW) by 0.6% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 21,672 shares of the medical research companys stock after selling 129 shares during the quarter. Kovitz Investment Group Partners []

Weaver Consulting Group boosted its holdings in Edwards Lifesciences Co. (NYSE:EW) by 0.3% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 38,722 shares of the medical research companys stock after purchasing an additional 118 shares during the quarter. Edwards []

Citigroup upgraded shares of Edwards Lifesciences (NYSE:EW) from a neutral rating to a buy rating in a research report released on Wednesday, Price Targets.com reports. Citigroup currently has $142.00 price objective on the medical research companys stock, up from their previous price objective of $120.00. Other equities analysts also recently issued research reports about the []

Edwards Lifesciences Co. (NYSE:EW) Equities research analysts at Jefferies Financial Group lifted their FY2022 earnings per share estimates for Edwards Lifesciences in a research note issued to investors on Thursday, December 9th. Jefferies Financial Group analyst A. Petrone now anticipates that the medical research company will earn $2.58 per share for the year, up [] The post Research Analysts Offer Predictions for Edwards Lifesciences Co.s FY2022 Earnings (NYSE:EW) appeared first on ETF Daily News .

Related Stocks: AAPL , NFLX , HCA , TGT , ADBE , SIVB , TEAM , DDOG , EW , WCN , LULU , DPZ , ATVI , LRCX , CAT , DIS , UBER , TWLO ,

Edwards Lifesciences (EW) expects to reach significant milestones in 2022 including new product launches and progress in multiple significant clinical trials.

Edwards Lifesciences (NYSE:EW) had its target price increased by SVB Leerink from $130.00 to $135.00 in a research report released on Thursday morning, Price Targets.com reports. The brokerage currently has an outperform rating on the medical research companys stock. SVB Leerink also issued estimates for Edwards Lifesciences Q1 2022 earnings at $0.59 EPS, Q2 2022 []

Legacy Bridge LLC decreased its holdings in shares of Edwards Lifesciences Co. (NYSE:EW) by 9.4% during the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 15,538 shares of the medical research companys stock after selling 1,612 shares during the quarter. Edwards Lifesciences comprises about 1.0% of []

Balasa Dinverno & Foltz LLC increased its stake in shares of Edwards Lifesciences Co. (NYSE:EW) by 27.2% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 6,177 shares of the medical research companys stock after buying an additional 1,320 shares during []

Balasa Dinverno & Foltz LLC grew its stake in shares of Edwards Lifesciences Co. (NYSE:EW) by 27.2% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 6,177 shares of the medical research companys stock after purchasing an additional 1,320 shares []

West Family Investments Inc. lifted its stake in shares of Edwards Lifesciences Co. (NYSE:EW) by 5.8% in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 2,410 shares of the medical research companys stock after acquiring an additional 132 shares during the period. []

Edwards Lifesciences Co. (NYSE:EW) Investment analysts at Piper Sandler dropped their Q2 2022 earnings estimates for shares of Edwards Lifesciences in a report released on Wednesday, December 8th. Piper Sandler analyst A. Maeder now expects that the medical research company will post earnings of $0.64 per share for the quarter, down from their previous []